Results 21 to 30 of about 67,212 (289)

Bisphosphonate-induced periprosthetic fracture: a cause of painful total hip arthroplasty [PDF]

, 2014
Background. Cases have been reported in the literature of periprosthetic fractures associated with the use of bisphosphonates occurring in the long term following a Total Hip Replacement (THR).
Bhattacharyya, Rahul, O’Neill, Gavin, Periasamy, Kumar, Spence, Stephanie   +3 more
core   +4 more sources

Adherence to Bisphosphonates among People Admitted to an Orthopaedic and Geriatric Ward at a University Hospital in Sweden

Pharmacy, 2018
Oral bisphosphonates are the first choice of therapy to reduce the risk of osteoporotic fractures. These medications have generally poor oral bioavailability, which may further be reduced by concomitant intake of certain foods and drugs; therefore, it is
Linnea Abramsson, Maria Gustafsson
doaj   +1 more source

Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. [PDF]

PLoS ONE, 2011
BACKGROUND: Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic drugs.
Longxiang Shen, Xuetao Xie, Yan Su, Congfeng Luo, Changqing Zhang, Bingfang Zeng   +5 more
doaj   +1 more source

Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. [PDF]

, 2019
PurposeOsteogenesis imperfecta (OI) predisposes people to recurrent fractures, bone deformities, and short stature. There is a lack of large-scale systematic studies that have investigated growth parameters in OI.MethodsUsing data from the Linked ...
A Lund, A Markmann, AD Letocha, AK Anissipour, Allison Tam, B Sykes, BJ Belt-Niedbala, Brendan Lee, BU Nwosu, C Land, D Gatti, David Cuthbertson, DO Sillence, DR Keene, EL Germain-Lee, ER Barros, F Rauch, F Rauch, FH Glorieux, Francis H. Glorieux, Frank Rauch, I Grafe, Jay R. Shapiro, JC Marini, JC Marini, JD Hald, Jeff Krischer, JM Tanner, K Graff, L Zeitlin, LA Dimeglio, Mahim Jain, Mary Mullins, Melanie Pepin, MG Seikaly, Michael B. Bober, Michaela Durigova, MS Aglan, N Bishop, N Bishop, Peter A. Smith, Peter H. Byers, R Sakkers, RH Engelbert, RH Engelbert, RM Patel, Robert D. Steiner, RT Hamza, S Bellur, Sandesh C. S. Nagamani, Sunil Bellur, T Palomo, T Yang, Tracy Hart, U Vetter, V. Reid Sutton, Y Takeuchi   +56 more
core   +2 more sources

The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis

Therapeutic Advances in Medical Oncology, 2019
Background: Adjuvant bisphosphonates reduce the rate of breast cancer recurrence in the bone and improve breast cancer survival. However, the risk of adverse events associated with bisphosphonate therapy for breast cancer remains poorly defined. Methods:
Yan-Li Yang, Zi-Jian Xiang, Jing-Hua Yang, Wen-Jie Wang, Ruo-Lan Xiang   +4 more
doaj   +1 more source

Long Term Bisphosphonate Use in Osteoporotic Patients; A Step Forward, Two Steps Back

Journal of Pharmacy & Pharmaceutical Sciences, 2012
Purpose. Bisphosphonates are the main class of drugs widely used in prevention and treatment of osteoporosis. Along with the beneficial effects, recent studies point to the harms of long-term treatment with bisphosphonates. Methods.
Pooneh Salari, Mohammad Abdollahi
doaj   +1 more source

Effect of bisphosphonates on bone giant cell tumor recurrence: a meta-analysis

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background We examined the impact of bisphosphonates as adjuvant therapy on the recurrence of giant cell bone tumors and the impact of various tumor stages and surgical techniques on this effect.
Marwa Mohsen, Hasnaa Osama, Mina Nicola, Haitham Saeed, Mohamed E. A. Abdelrahim   +4 more
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Oral Mucosal Ulcer Associated with Improper Usage of Bisphosphonate: A Case Report

Türk Osteoporoz Dergisi, 2023
Bisphosphonates are widely used agents for osteoporosis. Although bisphosphonates are generally well-tolerated drugs, especially oral forms may have gastrointestinal system side effects.
Şeyma Nur Bayındır, Bilinç Doğruöz Karatekin, Afitap İçağasıoğlu   +2 more
doaj   +1 more source

Use of bisphosphonates in bone pathology – benefits and risks [PDF]

Romanian Journal of Rheumatology, 2023
This article aims to establish, on the basis of medical literature and of the authors’ experience, whether bisphosphonates still have a role in treating skeletal diseases, with increased bone resorption. The effects of bisphosphonates on the bone tissue,
Dinu Antonescu, Cristian Ioan Stoica
doaj   +1 more source